Any current/future capex/capital investment/strategic investment?

Total capex incurred in Q1 FY'24 was INR 687 million, primarily on Suite 9 Combi-line. Adding new capabilities such as Microsphere Combi-line and additional Bag line at Pashamylaram facility, Hyderabad. Post-acquisition of Cenexi, assessing Cenexi's future cash requirements for capex geared towards operational improvements and asset creation for growth. Dedicated cross-functional team working on Cenexi integration to optimize operations and realize synergies. Investment focus on new technologies like oncology pre-filled syringe, colored products, and sterile gels from Cenexi’s portfolio. No si

Future growth expectations in sales/revenue/volumes?

U.S. Market: Steady sequential growth expected quarter-on-quarter with new launches driving about 20% growth in U.S. from new products and volumes; continued ramp-up of Enoxaparin volumes expected from next quarter after inventory rationalization. New Product Launches: 23 molecules launched in Q1 in U.S. with further 12-13 product launches planned next quarter; target around 40 product launches per year going forward. Base Business Growth: 4% year-on-year growth in base business revenue excluding acquisitions. Rest of World (ROW): Gradual business growth anticipated, with focus shifting

Future growth expectations in earnings/operating earnings/profits/EPS?

Base business grew 4% YoY in Q1FY'24; expected steady sequential growth in US market driven by new product launches and volume growth. Enoxaparin sales in US had inventory rationalization in Q1 but expected to pick up from next quarter. Launch target: Around 40 products annually in the US market including tech transfers. Shift from low-margin products (e.g., Heparin, Enoxaparin in ROW) toward higher-margin businesses like Cenexi CDMO operations with high gross margins (~76%). EBITDA margin (ex-Cenexi) maintained at healthy 30%; PAT margin at 21% in base business. Gross margin improve

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide specific quantitative details on the current or expected order book or pending orders for Gland Pharma as of Q1 FY24. However, management highlights: - A positive start to FY24 with revenue growth and strong operational performance. - Multiple product launches in the U.S., including 23 products launched in Q1 and plans for about 40 annual launches. - New launches and relaunches are driving volume growth, especially in the U.S. market. - The company is rebuilding business volumes with customers following recent contract shifts. - Several technology tran

Any current/future new fundraising through debt or equity?

No additional one-off costs or significant new fundraising through debt or equity anticipated at this point. All M&A-related costs have already been spent. Ongoing costs are primarily related to post-merger integration consultancy fees, which are not substantial. No explicit mention of planned new debt or equity fundraising in the call transcript. Focus remains on operational integration and efficiency improvements post Cenexi acquisition rather than new fundraising.

IN US

Sale is live|00:00:00left today

Gland Pharma LtdQ2 FY23Pharmaceuticals & Biotechnology

Gland Pharma Ltd Q2 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,315P/E: 29.5Market Cap: ₹30.8K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→U.S. Market: Steady sequential growth expected quarter-on-quarter with new launches driving about 20% growth in U.S. from new products and volumes; continued ramp-up of Enoxaparin volumes expected from next quarter after inventory rationalization.
→New Product Launches: 23 molecules launched in Q1 in U.S. with further 12-13 product launches planned next quarter; target around 40 product launches per year going forward.
→Base Business Growth: 4% year-on-year growth in base business revenue excluding acquisitions.
→Rest of World (ROW): Gradual business growth anticipated, with focus shifting to higher margin products and Cenexi portfolio, which showed 62% YoY revenue growth.
→India Market: 27% revenue growth in Q1 FY24.
→Cost Efficiency: Opportunities exist to improve operational efficiencies, reduce costs, and increase profitability.
→Oncology Products: Demand expected to remain high due to ongoing shortages, supporting growth in onco injectables segment.

Margin guidance

Category 3

→Base business grew 4% YoY in Q1FY'24; expected steady sequential growth in US market driven by new product launches and volume growth.
→Enoxaparin sales in US had inventory rationalization in Q1 but expected to pick up from next quarter.
→Launch target: Around 40 products annually in the US market including tech transfers.
→Shift from low-margin products (e.g., Heparin, Enoxaparin in ROW) toward higher-margin businesses like Cenexi CDMO operations with high gross margins (~76%).
→EBITDA margin (ex-Cenexi) maintained at healthy 30%; PAT margin at 21% in base business.
→Gross margin improvement and operational efficiencies expected from synergies with Cenexi including new technologies and cost reduction.
→Profit share expected to remain around 8-11%.
→Capex expected for Cenexi post-acquisition to drive operational improvements and future growth.
→Overall, management anticipates growth fueled by new launches, higher-margin portfolio, and integration synergies for improved earnings and profitability.

3 more insights locked — sign up free to unlock

Fundraise plans

→No additional one-off costs or significant new fundraising through debt or equity anticipated at this point.
→All M&A-related costs have already been spent.
→Ongoing costs are primarily related to post-merger integration consultancy fees, which are not substantial.
→No explicit mention of planned new debt or equity fundraising in the call transcript.
→Focus remains on operational integration and efficiency improvements post Cenexi acquisition rather than new fundraising.

Order book

→The transcript does not provide specific quantitative details on the current or expected order book or pending orders for Gland Pharma as of Q1 FY24.
→However, management highlights:
→ - A positive start to FY24 with revenue growth and strong operational performance.
→ - Multiple product launches in the U.S., including 23 products launched in Q1 and plans for about 40 annual launches.
→ - New launches and relaunches are driving volume growth, especially in the U.S. market.
→ - The company is rebuilding business volumes with customers following recent contract shifts.
→ - Several technology transfer projects and partnerships are underway to expand the high-margin product portfolio.
→While no explicit order backlog data is disclosed, the focus on multiple launches and ongoing supply contracts indicates a robust opportunity pipeline.

Capex plans

Yes

→Total capex incurred in Q1 FY'24 was INR 687 million, primarily on Suite 9 Combi-line.
→Adding new capabilities such as Microsphere Combi-line and additional Bag line at Pashamylaram facility, Hyderabad.
→Post-acquisition of Cenexi, assessing Cenexi's future cash requirements for capex geared towards operational improvements and asset creation for growth.
→Dedicated cross-functional team working on Cenexi integration to optimize operations and realize synergies.
→Investment focus on new technologies like oncology pre-filled syringe, colored products, and sterile gels from Cenexi’s portfolio.
→No significant one-time costs expected related to M&A; only minor consultancy fees anticipated for post-merger integration.
→Overall, capital investments are targeted to enhance operational efficiency, capacity expansion, and integration benefits over 1-2 years.

How does Gland Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Gland Pharma Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Gland Pharma Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio